Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Cancer Res. 2013 Jun 6;73(15):4697–4710. doi: 10.1158/0008-5472.CAN-13-0930

Figure 4. Progesterone therapeutic effects are mediated through the stromal progesterone receptor.

Figure 4

(A) Strategy for deletion of PR in the stroma of PTENKO tumors. (B) Stromal loss of PR induced progesterone resistance. PTEN null endometrial tumors with stromal PR expression regressed with progesterone therapy (n=6) (a-c) but persisted in the placebo treated group (n=6) (d-f). Conversely, when stromal PR was deleted, PTENKO endometrial tumors did not respond to progesterone (n=8) (g-i) and the histology was similar to placebo treated controls (n=8) (j-l). Cre-GFP induced loss of stromal PR was confirmed (i&l vs. c&f). Scale bars are 100 μm except where noted.